Anna-Laura Kretz

Decreased CK1δ expression predicts prolonged survival in colorectal cancer patients

J. Richter, U. Knippschild, S. Just, 2016, Tumor Biology.

CDK9 is a prognostic marker and therapeutic target in pancreatic cancer

J. Richter, U. Knippschild, F. Leithäuser, 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Friend or Foe: S100 Proteins in Cancer

S. von Karstedt, D. Henne-Bruns, J. Lemke, 2020, Cancers.

Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers

M. El-Bahrawy, H. Walczak, D. Kulms, 2021, Cell Death & Differentiation.

TRAILblazing Strategies for Cancer Treatment

U. Knippschild, S. von Karstedt, D. Henne-Bruns, 2019, Cancers.

The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma

U. Knippschild, S. von Karstedt, D. Henne-Bruns, 2018, International journal of molecular sciences.

Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy

U. Knippschild, S. von Karstedt, D. Henne-Bruns, 2018, Cancers.

CK1α overexpression correlates with poor survival in colorectal cancer

J. Richter, U. Knippschild, M. Fauler, 2018, BMC Cancer.

The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death

M. Kornmann, D. Henne-Bruns, J. Lemke, 2021, AntiCancer Research.

Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer

U. Knippschild, M. Kornmann, D. Henne-Bruns, 2023, Biomedicines.

CK1α overexpression correlates with poor survival in colorectal cancer

J. Richter, U. Knippschild, M. Fauler, 2018, BMC Cancer.